Premium
In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone
Author(s) -
Su Ying,
Zhan Yunyun,
Wang Benfu,
Wang SiCong,
Dai Dapeng,
Hu Guoxin,
Lin Han,
Lian Qingquan,
Cai Jianping
Publication year - 2017
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.1959
Subject(s) - cyp2d6 , metabolite , methadone , cytochrome p450 , pharmacology , allele , pharmacogenetics , enzyme , cyp2b6 , chemistry , isozyme , metabolism , medicine , genotype , cyp3a4 , biochemistry , gene
CYP2D6 is an important member of the cytochrome P450 (CYP450) enzyme super family, with at least 100 CYP2D6 alleles being previously identified. Genetic polymorphisms of CYP2D6 significantly influence the efficacy and safety of some drugs, which might cause adverse effects and therapeutic failure. The aim of this study was to clarify the catalytic activities of 24 CYP2D6 alleles on the oxidative in vitro metabolism of methadone. Reactions were incubated with 50–2000 µM methadone for 30 min at 37 °C and terminated by cooling to ‐80 °C immediately. Methadone and the major metabolite EDDP were analyzed by an ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS) system. Compared with wild‐type CYP2D6*1, most variants showed significantly altered values in V max and intrinsic clearance (V max /K m ). Only three variants (CYP2D6*88, *91 and E215K) exhibited markedly increased intrinsic clearance values, and one variant CYP2D6*94 showed no significant difference. On the other hand, the kinetic parameters of two CYP2D6 variants (CYP2D6*92 and *96) could not be determined because they had no detectable enzyme activity, whereas 18 variants exhibited significantly decreased values. To sum up, this study demonstrated that more attention should be paid in clinical administration of methadone to individuals carrying these CYP2D6 alleles. Copyright © 2016 John Wiley & Sons, Ltd.